Stockscreener 앱 받기
0.203
1.77%
-0.00365
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Top US Stock Movers: Gainers and Losers in Today's Session - ChartMill
Form 8K VistaGen Therapeutics Inc For: 25 September By Investing.com - Investing.com Nigeria
Three anxiety drug trials missed their goals. Vistagen (VTGN) proposes another after one met its goal. - Stock Titan
Vistagen Therapeutics Shares Positive Fasedienol Nasal Spray Data at Psych Congress 2026 - Kalkine Media
Top US Stock Movers for 2026-09-23: VSA Up 135.0%, JAGX Down 73.74% - ChartMill
Small Cap Stocks To Keep An Eye OnSeptember 23rd - MarketBeat
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Top US Stock Movers: Gainers and Losers in Today's Session - ChartMill
Wednesday's session: top gainers and losers - ChartMill
Gapping stocks in Wednesday's session - ChartMill
Gapping stocks in Wednesday's session - ChartMill
Gap-Up and Gap-Down Stocks: Sept. 23, 2026 Session - ChartMill
Gap-Up and Gap-Down Stocks: Sept. 23, 2026 Session - ChartMill
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Year‑long nasal spray use at Vistagen (NASDAQ: VTGN) lowers social anxiety scores as FDA talks approach - Stock Titan
Vistagen Therapeutics shareholders elect board members and approve key proposals By Investing.com - Investing.com Australia
Form 8K VistaGen Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria
Form 8K VistaGen Therapeutics Inc For: 11 September By Investing.com - Investing.com Canada
Form 8K VistaGen Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa
VistaGen Stockholders Reaffirm Board, Governance and Oversight - TipRanks
Vistagen Therapeutics shareholders elect board members and approve key proposals - Investing.com Canada
Stockholders at Vistagen (NASDAQ: VTGN) back board slate, executive pay and KPMG - Stock Titan
Vistagen Therapeutics shareholders elect board members and approve key proposals - Investing.com Nigeria
Vistagen to Present at Psych Congress 2026 - GlobeNewswire
VistaGen Therapeutics Inc. (VTGN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vistagen Therapeutics (VTGN) Slides 4.31% to $0.24, Testing Key Support at $0.23Box Spread - vinanet.vn
Vistagen Therapeutics Lawsuit: Company Seeks Dismissal of Investor Securities Claims - TipRanks
Vistagen Therapeutics (VTGN) Slides 4.31% to $0.24, Testing Key Support at $0.23IPO Entry Watch - dars.gov.et
Vistagen Therapeutics (VTGN) Slides 4.31% to $0.24, Testing Key Support at $0.23ALMA Signal - dars.gov.et
VistaGen Therapeutics Inc. (VTGN) Peer Comparison – Compare with Others - Value Research
VistaGen Therapeutics Inc. (VTGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Vistagen (VTGN) Trading: Gains 1.20% to Reach $0.24 on the Day; the Current Price Sits Inside the Supplied Technical Range in the Available RecordLeveraged ETF Flow - vinanet.vn
VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates - Investing.com Canada
VistaGen Therapeutics (VTGN) Institutional Ownership 2026 - MarketBeat
Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN - Moomoo
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating - Moomoo
Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A - Stock Titan
Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake - Stock Titan
Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure - Stock Titan
Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Vistagen Therapeutics (VTGN) investor reports 4.24M-share, 9.9% stake - Stock Titan
Vistagen Therapeutics Releases Q1 2027 Financial Results - AlphaStreet
VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates - Investing.com UK
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com India
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com Canada
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com UK
Vistagen Reports $1.5 Million Revenue and $13.0 Million Quarterly Net Loss - Moomoo
Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026 - TradingView
VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - Moomoo
1.19%
자본화:
|
볼륨(24시간):